Immunic (NASDAQ:IMUX) Earns “Buy” Rating from HC Wainwright

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $10.00 price objective on the stock. HC Wainwright also issued estimates for Immunic’s Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS and Q4 2025 earnings at ($0.18) EPS.

Other equities analysts also recently issued research reports about the stock. StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th. William Blair started coverage on Immunic in a research note on Tuesday, March 25th. They set an “outperform” rating on the stock. Finally, D. Boral Capital restated a “buy” rating and set a $17.00 price objective on shares of Immunic in a report on Thursday, April 10th. One investment analyst has rated the stock with a sell rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Immunic currently has a consensus rating of “Buy” and a consensus price target of $13.20.

Immunic Price Performance

Shares of NASDAQ IMUX opened at $0.94 on Tuesday. The firm’s 50-day moving average is $1.08 and its two-hundred day moving average is $1.15. Immunic has a 12-month low of $0.83 and a 12-month high of $2.11. The company has a market capitalization of $84.97 million, a PE ratio of -0.77 and a beta of 1.91.

Institutional Trading of Immunic

Several institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new position in Immunic in the third quarter valued at $50,000. Invesco Ltd. acquired a new position in shares of Immunic in the 4th quarter valued at about $37,000. Jane Street Group LLC grew its holdings in shares of Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the period. HB Wealth Management LLC acquired a new stake in Immunic during the 4th quarter worth approximately $81,000. Finally, Barclays PLC purchased a new position in Immunic in the fourth quarter valued at approximately $84,000. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.